Maxxcardio LA 2mg (3 blisters x 10 tablets/box)

Indications

• Maxxcardio LA 2mg is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including β-adrenoceptor antagonists, diuretics, and ACE-inhibitors.

Contraindications

• Hypersensitivity to lacidipine or to any of the excipients.
• Lacidipin should only be used with great care in patients with a previous allergic reaction to another dihydropyridine because there is a theoretical risk of cross-reactivity.
• As with other calcium antagonists, lacidipine should be discontinued in patients who develop cardiogenic shock and unstable angina. In addition, dihydropyridines have been shown to reduce coronary arterial blood-flow in patients with aortic stenosis and in such patients lacidipine is contraindicated.
• Lacidipin should not be used during or within one month of a myocardial infarction.

Compositon/Ingredients

Dosage and administration

Adults

• The treatment of hypertension should be adapted to the severity of the condition, and according to the individual response.
• The recommended initial dose is 2 mg once daily. The dose may be increased to 4mg (and then, if necessary, to 6mg) after adequate time has been allowed for the full pharmacological effect to occur. In practice, this should not be less than 3 to 4 weeks.
• Daily doses above 6mg have not been shown to besignificantly more effective.
• Lacidipin should be taken at the same time each day, preferably in the morning.
• Treatment with lacdipin may be continued indefinitely.

Patients with hepatic impairment

• Lacidipin is metabolised primarily by the liver and therefore in patients with hepatic impairment, the bioavailability of lacidipin may be increased and the hypotensive effect enhanced. These patients should be carefully monitored, and in severe cases, a dose reduction may be necessary.

Patients with kidney disease

• As lacidipine is not cleared by the kidneys, the dose does not require modification in patients with kidney disease.

Paediatric

• No experience has been gained with lacidipin in children.

Precaution

• Lacidipin should be used with caution in patients with pre-existing abnormalities in the activity of the SA and AV nodes.
• Lacidipin should be used with caution in patients with congenital or documented acquired QT prolongation. Lacidipin should also be used with caution in patients treated concomitantly with medications known to prolong the QT interval such as class I and III antiarrhythmics, tricyclic antidepressants, some antipsychotics, antibiotics (e.g. erythromycin) and some antihistamines (e.g. terfenadine).
• Lacidipin should be used with caution in patients with poor cardiac reserve.
• There is no evidence that lacidipine is useful for secondary prevention of myocardial infarction.
• The efficacy and safety of lacidipin in the treatment of malignant hypertension has not been established.
• Lacidipin should be used with caution in patients with impaired liver function because antihypertensive effect may be increased.
• There is no evidence that lacidipine impairs glucose tolerance or alters diabetic control.
• Maxxcardio LA contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
• Lacidipin should only be used in pregnancy when the potential benefits for the mother outweigh the possibility of adverse effects in the foetus or neonate. The possibility that lacidipin can cause relaxation of the uterine muscle at term should be considered.
• Lacidipin should only be used during breastfeeding when the potential benefits for the mother outweigh the possibility of adverse effects in the foetus or neonate.
• Lacidipin may cause dizziness. Patients should be warned not to drive or operate machinery if they experience dizziness or related symptoms.

Storage

Store at temperature below 30°C, protect from light.